Goldman initiated coverage on ArriVent BioPharma with a new price target
$AVBP
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $27.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $37.00 | Buy | B. Riley Securities |
| 3/10/2025 | $45.00 | Buy | Guggenheim |
| 7/22/2024 | $35.00 | Outperform | Oppenheimer |
| 4/30/2024 | $25.00 | Buy | H.C. Wainwright |
| 2/20/2024 | $35.00 | Buy | Jefferies |
| 2/20/2024 | $27.00 | Buy | Goldman |
| 2/20/2024 | $30.00 | Buy | Citigroup |